All In Biotech

Drug Trial Radar · NCT05392946

Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

Phase 1/2 Trial of Iberdomide in Combination With Daratumumab, BortEzomib and DexamethAsone in Patients With Newly Diagnosed Multiple MyeLoma (IDEAL)

Last checked: Nov 19, 2026Latest source record: Oct 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

49

Actual

Start

Aug 11, 2022

Primary completion

Sep 18, 2026

Study completion Sep 29, 2028

Sponsor

Lead sponsor
Mayo ClinicAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
May 26, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase I/II trial studies the side effects and best dose of iberdomide and how well it works in combination with daratumumab, bortezomib, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Immunotherapy with iberdomide, may induce changes in body's immune system and may interfere with the ability of tumor cells to grow and spread. Daratumumab is a monoclonal antibody that may interfere with the ability of cancer cells to grow and spread. Bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving iberdomide in combination with daratumumab, bortezomib, and dexamethasone may kill more cancer cells in patients with newly diagnosed multiple myeloma.

Conditions

  • Plasma Cell Myeloma

Interventions

  • BortezomibDrug

    Given SC

  • DaratumumabBiological

    Given SC

  • DexamethasoneDrug

    Given PO

  • IberdomideDrug

    Given PO

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum tolerated dose (MTD) of iberdomide (Phase I)Time frame: Up to 12 cycles. Each cycle is 28 days.
  2. Complete response rate (Phase II)Time frame: Up to 3 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Mayo Clinic in Rochester

    Rochester, Minnesota

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.